Abstract 116TiP
Background
Immune checkpoint inhibitors (ICIs) are now standard for many tumors, but many patients don't respond or develop resistance. Consequently, novel immunotherapeutic drugs are in clinical trials, showing promise for synergy with ICIs. This umbrella trial will evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumors after progression in clinical trials.
Trial Design
This study aims to enroll 100 patients with advanced solid tumors who have progressed after clinical trial treatments. It uses an open-label, single-arm, multi-cohort umbrella design. Participants will receive Triplimab in either combination or sequential regimens. Selection focuses on phase I trials of novel immunotherapies, including tumor vaccines, cell therapy, and innovative ICIs. The trial will have cohorts for combination therapy, sequential therapy, and real-world scenarios. In the combination therapy cohort, patients will be stratified based on their initial investigational drug. Those who progressed on drug A (SG1827, CD80 fusion protein) or B (ABO2011, mRNA vaccine encoding IL-12) will receive their respective drug with Triplimab at 3 mg/kg IV every two weeks, continuing their prior treatment regimen (cohort A, B). More cohorts will open in the future. The sequential therapy cohort will uniformly receive Triplimab regardless of frontline trial drugs. The real-world cohort includes patients who don't meet the interventional criteria or opt out, with only data collection. Key eligibility criteria are advanced solid tumors, progression after first-line clinical trials, and no longer benefiting from initial treatment. Exclusion criteria include serious immune-related adverse events or tumor hyperprogression after prior immunotherapy. The primary endpoint is safety and tolerability, with adverse events graded by CTCAE v5.0. Secondary endpoints include efficacy assessments like objective response rate, disease control rate, duration of response, progression-free survival, and overall survival. This trial began in May 2024 and has enrolled 3 patients at the time of submission.
Clinical trial identification
NCT06612632.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract